Glenmark Launches Authorized Generic Version of INLYTA Tablets in the US

manufacturing-news
Image Courtesy: Pixabay

Glenmark Pharmaceuticals Inc, USA, a subsidiary of Glenmark Pharmaceuticals Limited, has launched Axitinib Tablets in 1 mg and 5 mg strengths in the United States. The product is an authorised generic version of INLYTA® (axitinib) tablets, further expanding the company’s portfolio of affordable pharmaceutical treatments in the US market.

According to IQVIA sales data for the 12-month period ended September 2026, INLYTA tablets recorded annual sales of approximately US$538.4 million in the United States, highlighting the commercial significance of the product in the oncology segment.

The launch reinforces Glenmark’s strategy of expanding its presence in the US pharmaceutical market through the introduction of products that address important healthcare requirements. The addition of axitinib to its portfolio also strengthens the company’s focus on providing patients and healthcare professionals with access to quality and affordable treatment options.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, Glenmark Pharmaceuticals, said the introduction of Axitinib Tablets reflected the company’s continued commitment to improving access to quality, affordable medicines for patients in the United States. He added that the addition of the product would further strengthen Glenmark’s portfolio and its efforts to address the changing requirements of patients and healthcare providers. Axitinib is marketed under the reference brand INLYTA® and belongs to the oncology treatment segment. The availability of its authorised generic version in two strengths adds to Glenmark’s range of pharmaceutical offerings in the US market.

The launch is part of Glenmark’s broader strategy to strengthen its global generics business while expanding its presence in specialised therapeutic areas. The company continues to leverage its research and development capabilities, manufacturing infrastructure and international commercial network to introduce pharmaceutical products across key markets.

With a growing portfolio spanning branded formulations, innovative medicines, generics and consumer healthcare, Glenmark remains focused on combining pharmaceutical innovation with wider access to treatment. Its established capabilities in oncology, respiratory care and dermatology provide a foundation for further expansion across global markets.

Glenmark Pharmaceuticals Limited (BSE: 532296; NSE: GLENMARK) is a global, research-driven pharmaceutical company focused on innovation and accessibility. The company develops and commercialises therapies aimed at addressing significant healthcare needs while expanding access to high-quality and affordable medicines.

Glenmark operates 11 manufacturing facilities across four continents, supported by six research and development centres, and has a commercial presence in more than 80 countries. Its diversified portfolio includes branded formulations, innovative products, generics and consumer healthcare offerings, with key therapeutic focus areas encompassing respiratory diseases, dermatology and oncology.

The company continues to invest in research, product development and manufacturing capabilities to strengthen its global pharmaceutical operations. According to Scrip 100 rankings, Glenmark was among the world’s top 100 biopharmaceutical companies by pharmaceutical sales in 2024.